How OR6A2 and octanal on monocytes relate to outcomes after myocardial ischemia-reperfusion injury
Official title: Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury
Run by Southeast University, China · NCT07100457 · Data updated 2026-11-12
This project tries to see if the OR6A2 receptor on monocytes and blood levels of octanal are linked to inflammation and later heart complications in people who had myocardial ischemia-reperfusion injury after PCI.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Southeast University, China Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | September 1, 2019 |
| Main results expected | August 30, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | August 3, 2025 |
| Trial ID | NCT07100457 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (age 18–90) with angiographically confirmed coronary artery disease who had an acute myocardial infarction treated with primary PCI and were diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
✕Probably not a fit
Patients with active systemic infections, advanced heart failure (NYHA class III–IV), acute cerebrovascular events, myocarditis, cardiomyopathy, refractory ventricular arrhythmias, recent malignancy treatment, severe renal failure (eGFR <30 or dialysis), or Child-Pugh class C liver disease are excluded and unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study of patients who experienced myocardial ischemia-reperfusion injury after primary percutaneous coronary intervention. Investigators measure OR6A2 expression on monocyte subtypes, plasma octanal, and systemic oxidative stress and inflammatory biomarkers from blood samples taken after revascularization. They then correlate these molecular profiles with major adverse cardiovascular events identified during a 44-month clinical follow-up. The goal is to identify biomarker patterns that predict clinical outcomes and could support personalized risk stratification after revascularization.
Why it matters
Potential benefit: If successful, the findings could identify blood biomarkers that help predict which patients are at higher risk for complications after revascularization and guide more personalized follow-up or treatment.
How similar studies have gone: This line of inquiry is relatively novel—olfactory receptor signaling on immune cells like OR6A2 is an emerging area with limited direct clinical data, although biomarker correlations with inflammation and outcomes after reperfusion have been reported in related work.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period. 2. Age 18-90 years inclusive. Exclusion Criteria: 1. Active systemic infections. 2. Advanced heart failure (NYHA class III-IV). 3. Acute cerebrovascular conditions. 4. Active myocarditis. 5. cardiomyopathy. 6. Refractory ventricular tachycardia/fibrillation. 7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ). 8. Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m2 or dialysis dependence). 9. Child-Pugh class C hepatic dysfunction.
Where it's running
-
Department of Cardiology, Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Wenbin Lu, PhD
- Email: 101012092@seu.edu.cn
- Phone: +86 13605185175
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Avoiding graft recooling after normothermic perfusion in liver transplantation
This trial tests whether skipping the cooling step before placing a donor liver into a recipient helps outcomes for adults receiving livers preserved with normothermic or sequential perfusion.
-
Monitoring blood markers during DIEP flap breast reconstruction
We will see if measuring inflammation and oxidative stress markers in blood before and during the first 72 hours after DIEP flap reconstruction helps map recovery patterns for women having immediate breast reconstruction after mastectomy.
-
BX-001N to prevent kidney injury after cardiac surgery with total circulatory arrest
This study will see if BX-001N can prevent acute kidney injury and later major kidney problems in adults undergoing cardiac surgery with total circulatory arrest.
-
Using remote ischemic conditioning to improve outcomes for patients undergoing off-pump coronary artery bypass grafting
This study is testing if a special treatment called remote ischemic conditioning can help patients with coronary artery disease recover better after heart surgery without using a heart-lung machine.
-
Infusion of sodium lactate after cardiac arrest
This study is testing if giving a special solution called sodium lactate to patients who have just been revived from cardiac arrest can help protect their brain and reduce damage.
-
Exploring the effects of obstructive sleep apnea on vascular surgery outcomes
This study is testing how obstructive sleep apnea might affect recovery and complications in patients having surgery to repair an abdominal aortic aneurysm.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.